Airway Medix S.A. Signs Distribution Agreement with International Partner: Key Step in Company's Transformation into a Global Sales Organization

Warsaw, 20 May 2025: Airway Medix S.A., an innovative company in the MedTech sector, continues its dynamic transformation from a research and development entity into a fully operational, international sales company. On 14 May 2025, the Company signed a distribution agreement with a foreign medical partner for the introduction of its Cuffix and Oral Care products to the market outside the European Union.

The distribution agreement marks a significant milestone in Airway Medix's strategy to generate stable operating revenues from product sales. The execution of the contract will be based on individual orders placed by the international partner, allowing for flexible and efficient supply management.

"The interest demonstrated by our financial and distribution partners confirms that the innovative solutions offered by Airway Medix are highly valued in the medical market. Our next steps will focus on gathering hospital evidence and expanding into new markets, including Europe and the United States", said Anna Aranowska-Bablok, CEO of Airway Medix S.A.

Airway Medix is actively conducting regulatory work to be ready to fulfil the first order under the new distribution agreement within the current quarter. Furthermore, the Company continues discussions with additional potential partners both within and outside the European Union.

About Airway Medix S.A.: Airway Medix S.A. focuses on the research, development and commercialization of innovative single-use devices for mechanically ventilated patients in Intensive Care Units (ICUs), as well as life-threatening patients and anesthesiology departments. The products offered by Airway Medix address the most pressing clinical needs and fill a gap in current medical devices. Airway Medix S.A. has been listed on the Warsaw Stock Exchange since 2014.